In vivo antitumor activity of tetrahydrobenz(a)anthraquinone derivatives.
Female rats bearing DMBA induced mammary carcinomas were treated with a new anthraquinone derivative related to mitoxantrone. The drug was administered at a dose of 5 mg/kg daily for 10 days. Tumor regression was noted in 78% of the animals with growth rate reduced from +74.91% to -12.60%. The results demonstrate that replacement of a polar hydroxy group of mitoxantrone with a nonpolar hydrocarbon moiety does not impair its antitumor activity and in fact may influence its availability to endocrine systems.
Morreal
C E
CE
Breast Cancer Research Unit, Roswell Park Memorial Institute, Buffalo, New York 14263.
Sinha
D K
DK
White
C J
CJ
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D008942:Mitoxantrone / Q000031:analogs & derivatives*; D051381:Rats; D011919:Rats, Inbred Strains; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D008942:Mitoxantrone